Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $0.63 in the last session, down -5.03% from day before closing price of $0.66. In other words, the price has decreased by -$5.03 from its previous closing price. On the day, 3.02 million shares were traded.
Ratios:
We take a closer look at LXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.22 and its Current Ratio is at 2.22. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on March 05, 2025, Downgraded its rating to Market Perform and sets its target price to $1 from $2 previously.
On June 17, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.Leerink Partners initiated its Outperform rating on April 30, 2024, with a $5 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 15 ’24 when COATS LONNEL bought 300,000 shares for $1.60 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.29 while its Price-to-Book (P/B) ratio in mrq is 1.85.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $2.45, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 10.27%, while the 200-Day Moving Average is calculated to be -36.54%.
Shares Statistics:
A total of 363.18M shares are outstanding, with a floating share count of 177.07M. Insiders hold about 51.24% of the company’s shares, while institutions hold 26.54% stake in the company.
Earnings Estimates
The current market rating for Lexicon Pharmaceuticals Inc (LXRX) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.05 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.23 and -$0.38 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.36, with 5.0 analysts recommending between -$0.2 and -$0.53.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for LXRX’s current fiscal year. The highest revenue estimate was $50.8M, while the lowest revenue estimate was $1.26M, resulting in an average revenue estimate of $13.83M. In the same quarter a year ago, actual revenue was $31.08MBased on 5 analysts’ estimates, the company’s revenue will be $12.47M in the next fiscal year. The high estimate is $27.5M and the low estimate is $5.81M.
